ClinConnect ClinConnect Logo
Search / Trial NCT00437840

A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

Launched by GLAXOSMITHKLINE · Feb 20, 2007

Trial Information

Current as of April 25, 2025

Completed

Keywords

Healthy Volunteers, Tolerability, Pharmacokinetics, Pharmacodynamics Safety, Smoking,

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

  • Inclusion criteria:
  • Healthy adult male smoker between the ages of 18 and 50 years
  • Body weight greater than 50kg and BMI between 18.5-29.9 kg/m2.
  • No abnormalities on the medical, psychiatric or laboratory evaluation
  • Smoke on average more than 20 but less that 40 cigarettes per day for the past year and not tried to give up in the 3 months before the study.
  • Exclusion criteria:
  • History of psychiatric disorder or sleep disorder.
  • Receiving treatment for smoking cessation.
  • Use tobacco products other than cigarettes.

Trial Officials

GSK Clinical Trials

Study Director

GlaxoSmithKline

About Glaxosmithkline

GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.

Locations

Berlin, , Germany

Berlin, , Germany

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials